Hyderabad, Telangana, India, October 2024 — Gland Pharma Limited has announced the appointment of Shyamakant Giri as its new Chief Executive Officer (CEO). With vast experience in the pharmaceutical and healthcare sectors, Giri will lead Gland Pharma’s strategic initiatives and global expansion. He brings a proven track record of driving growth, managing large-scale operations, and developing strategic business ventures across emerging markets. His expertise will be pivotal in propelling Gland Pharma into its next phase of innovation and operational efficiency.
The current CEO, Srinivas Sadu, will transition to the role of Executive Chairman, continuing to support Gland Pharma’s growth strategy and ensuring a seamless leadership transition.
Before joining Gland Pharma, Shyamakant Giri was the Managing Director & President – India & Emerging Markets at Amneal Pharmaceuticals, where he led the company’s commercial expansion across regions such as India, Africa, Gulf, CIS, LATAM, China, and South Asia.
Prior to Amneal, Giri served as the Chief Executive Officer at Rivaara Labs, a startup that he scaled by establishing 14 molecular labs, launching two proprietary point-of-care devices, and achieving significant milestones in COVID testing, pathology verticals, and private equity investments.
Giri also spent over 17 years at Abbott, where he held various senior roles, including General Manager & Country Head for the India region and Africa, Director of EPD Hospital Business, and Country Manager for AbbVie Business in India. His tenure at Abbott was marked by significant growth in diagnostics and hospital care segments across multiple regions.
Earlier in his career, Giri held managerial roles at Wockhardt Ltd., where he honed his skills in product management and sales strategy, driving growth across the pharmaceutical sector.
About Gland Pharma Limited
Gland Pharma Limited, established in 1978 in Hyderabad, India, is one of the fastest-growing small-molecule generic injectables companies with a presence in over 60 countries, including the United States, Europe, Canada, and Australia. The company operates seven manufacturing facilities in India and offers a diverse range of sterile injectables across therapeutic segments, including oncology and ophthalmics. Gland Pharma is focused on delivering affordable, high-quality injectables to meet global healthcare needs.
Read Also : Imagination in a Disrupted Age: Navigating the Future with Curiosity and Empathy
